Download 'Too Hot', an exclusive Specials track from iTunes
Heygate hadn’t played first-class cricket in 14 years but, even so, he strapped pads over his suit and headed to the wicket. Unfortunately his war wounds and arthritis were such that he couldn’t hobble to the crease in time and was ruled “out, absent”.
Cricket, tennis, rugby, football and every other game that has become professional are no longer associated with lazy days in the sun, or played as an excuse for a post-match booze-up on a Saturday evening. Games these days are competitive and won only if the athletes are prepared to sacrifice their long-term muscular-skeletal systems for the greater glory of their team and encouraging entries on their bank statements.
The risk of being asked to make an irremedial sacrifice may not be as great as it was for the Roman gladiator but the same principle applies. The crowds have their spectacles and, in return, the players receive medals and, occasionally, a cup to carry home to the trophy cupboard. They also get early arthritic hips, damaged knees and ankles, painful, immobile shoulders and prematurely aged spines.
Whatever the sport, an athlete, once he is no longer able to maintain the rigorous exercise schedules needed to remain in peak athletic condition, becomes a candidate for obesity and cardiovascular and metabolic diseases.
As most of the immediate damage is to joints, tendons and ligaments, the role of anti-inflammatory drugs is all-important in the treatment of athletes. For the past 40 years doctors have used aspirin and paracetamol to supplement the non-steroidal anti-inflammatory drugs (NSAIDs) that counteract the pain and stiffness of inflamed joints.
The increasing number of NSAIDs include ibuprofen, indomethacin, mefenamic acid (Ponstan), diclofenac (Voltarol) and my favourite, Arthrotec — a combination of diclofenac and misoprostol. The latter serves to avert some of the gastrointestinal troubles that can result from taking NSAIDs.
The NSAIDs inhibit the enzyme COX-1 (which speeds up the action of chemical messengers, called prostaglandins, within the stomach). An apparent advance about 15 years ago was the introduction of COX-2 inhibitors. These are less likely to cause the potentially dangerous gastrointestinal bleeding that is the curse of COX-1 NSAIDs.
Unfortunately the COX-2s were associated with a small increase in the incidence of heart disease and many were withdrawn as a result.
This was perhaps overly cautious — no effective drug is without side effects. Some former cricketers might be prepared to increase their chances of coronary arterial disease by a fraction if it meant that they could walk to the shops, climb stairs and enjoy the odd trip to Lord’s.
Etoricoxib (Arcoxia), one of the COX-2 inhibitors that is a reliable treatment for the pain and inflammation caused by arthritis, is equally effective in dealing with other forms of arthritis and inflammatory conditions.
Fortunately it escaped the strictures applied to other selective COX-2 inhibitors. A recent study conducted in 38 countries over four years, involving 34,000 patients, has shown that my faith in etoricoxib has not been misplaced.
The COX-2s were developed to provide pain relief and anti-inflammatory treatment that is just as effective as that provided traditionally by the COX-1 NSAIDs, but with improved gastrointestinal safety.
The trial has shown that there was no increased incidence of coronary thrombosis in those patients taking etoricoxib instead of diclofenac, which is the most commonly prescribed anti-inflammatory agent worldwide.
In patients taking etoricoxib there was the expected reduction in gut problems. When extoricoxib was given in very large doses there was some increase in blood pressure and its associated symptoms, but these were not found in patients given the usual standard dose.
SPORT CAN SERIOUSLY DAMAGE YOUR HEALTH
It is not only the traditional sports of cricket, football, tennis and rugby that are associated with injury:
Win a luxury weekend to Newcastle and its neighbour Gateshead, find out more here
Risk, resilience and embracing new technology
Industry sectors news at a glance. Interactive heatmap, video and podcast
Discover the power of collective thinking. Submit a solution and be in with a chance to win a Media Hub Home Entertainment System
The inside track on current trends in the charity, not for profit and social enterprise sectors
Everything the Business Traveller needs to know to make a better trip
Make the most of the summer and enter our fabulous photographic competition, you could win a £5000 holiday
Corsica is an island of beauty and contrast, an ideal holiday destination
Enjoy further reading from Travel to Fashion, Business to Sport, discover more




Shortcuts to help you find sections and articles
The clever way to lease a new car is with Car leasing made simple™
2009
per month on 36-month
Personal Contract Hire (PCH)
2008
42850
Car Insurance
£24,250 - £30,346
MI5
London
£60,000
The Environment Agency
Bristol
Up to £90K
Boots
Midlands
OTE £85k
Credit Protection Association
Nationwide Opportunities
Completely London
Luxury Condo's in Manhattan with NYC views
The best new homes in Wimbledon?
Nationwide
Fabulous Cruise And Cruise & Stay Offers Including Virgin Atlantic Flights Prices Start From Only £699pp!
Last Minute Cruise And Cruise & Stay Offers. Med From £499pp, Caribbean From £699pp!
5 star quality at a 3 star price.
8 fabulous Canadian cities ...you won’t find cheaper
Contact our advertising team for advertising and sponsorship in Times Online, The Times and The Sunday Times, or place your advertisement.
Times Online Services: Dating | Jobs | Property Search | Used Cars | Holidays | Births, Marriages, Deaths | Subscriptions | E-paper
News International associated websites: Globrix Property Search | Property Finder | Milkround
Copyright 2009 Times Newspapers Ltd.
This service is provided on Times Newspapers' standard Terms and Conditions. Please read our Privacy Policy.To inquire about a licence to reproduce material from Times Online, The Times or The Sunday Times, click here.This website is published by a member of the News International Group. News International Limited, 1 Virginia St, London E98 1XY, is the holding company for the News International group and is registered in England No 81701. VAT number GB 243 8054 69.